Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | AXL | P30530 | 1/20 | 0.54 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24799800 | 1.00 | KMT2A (0.68) | KMT2AAXLHPGDSMEN1PDE4A | |
| SCHEMBL2302601 | 1.00 | KMT2A (0.68) | KMT2AAXLHPGDSMEN1PDE4A | |
| SCHEMBL29860203 | 0.98 | KMT2A (0.65) | KMT2AAXLHPGDSMEN1PDE4A | |
| SCHEMBL1976634 | 0.98 | KMT2A (0.65) | KMT2AAXLHPGDSMEN1PDE4A | |
| SCHEMBL586310 | 0.95 | KMT2A (0.60) | KMT2AAXLHPGDSMEN1AURKA | |
| SCHEMBL1773741 | 0.92 | KMT2A (0.55) | KMT2AAXLHPGDSMEN1AURKA | |
| SCHEMBL23967510 | 0.88 | KMT2A (0.54) | KMT2AAXLAURKAAURKBJAK1 | |
| SCHEMBL13649059 | 0.87 | KMT2A (0.51) | KMT2AAXLHPGDSMEN1AURKA | |
| SCHEMBL19763757 | 0.86 | KMT2A (0.51) | KMT2AAXLAURKAAURKBJAK1 | |
| SCHEMBL13649033 | 0.84 | KMT2A (0.49) | KMT2AAXLMEN1JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118084902-B | 2-Aminothiazole pyrimidopyridone compound or pharmaceutically acceptable salt or stereoisomer, preparation method and application | 赣南师范大学 | 2024-10-29 | — | — | CN | disclosed |
| CN-118084902-A | 2-Aminothiazole pyrimidopyridone compound or pharmaceutically acceptable salt or stereoisomer, preparation method and application | 赣南师范大学 | 2024-05-28 | — | — | CN | disclosed |
| EP-3481826-B1 | TYROSINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2021-11-03 | — | — | EP | disclosed |
| US-9309252-B2 | Pyrrolopyrimidine compounds as inhibitors of CDK4/6 | NOVARTIS AG (CH) | 2016-04-12 | — | — | US | disclosed |
| EP-2536730-B1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2015-07-08 | — | — | EP | disclosed |
| US-20150099737-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2015-04-09 | — | — | US | disclosed |
| US-8957074-B2 | Pyrrolopyrimidine compounds as inhibitors of CDK4/6 | NOVARTIS AG (CH) | 2015-02-17 | — | — | US | disclosed |
| US-20130150342-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
| CN-102918043-A | Pyrrolopyrimidine compounds as CDK4/6 inhibitors | NOVARTIS AG | 2013-02-06 | — | — | CN | disclosed |
| EP-2536730-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | Novartis AG (CH) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011101409-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099737-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | CDK4, CDK6, CCNT1 | KMT2A 541/4885AXL 1652/4885HPGDS 2198/4885 |
| US-20130150342-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | CDK4, CDK6, CCNT1 | KMT2A 566/4885AXL 1626/4885HPGDS 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.